Welcome to our dedicated page for Nuvectis Pharma SEC filings (Ticker: NVCT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nuvectis Pharma, Inc. filings document the regulatory disclosures of a Nasdaq-listed clinical-stage oncology drug developer with common stock registered under the Exchange Act. Recent Form 8-K reports furnish quarterly and annual financial results, corporate updates, and exhibit press releases describing development activity for NXP900 and related operating progress.
Proxy materials cover annual meeting matters, director elections, auditor ratification, board composition, and stockholder voting procedures. Other material-event filings record governance changes such as director appointments, while cover-page disclosures identify Nuvectis as an emerging growth company and list its common stock trading on the Nasdaq Capital Market under NVCT.
Nuvectis Pharma, Inc. reported an equity award to its Chairman and CEO, Ron Bentsur. On 01/06/2026, he was granted 150,000 shares of restricted common stock at a price of $0 per share. These restricted shares will vest in equal annual installments over three years, starting on the first anniversary of the grant date, as long as he continues to serve with the company on each vesting date.
After this grant, Mr. Bentsur beneficially owns 3,675,924 shares of Nuvectis Pharma common stock, held directly, which includes previously granted restricted shares.
Nuvectis Pharma, Inc. reported an equity grant to a senior officer. Chief Science & Business Officer Enrique Poradosu received 150,000 shares of restricted common stock on January 6, 2026, at a stated price of $0 per share, reflecting a compensatory award rather than an open-market purchase.
The 150,000 restricted shares will vest in equal annual installments over three years, beginning on the first anniversary of the grant date, and are conditioned on Mr. Poradosu’s continued service on each vesting date. Following this grant, he beneficially owned 1,806,319 shares of Nuvectis common stock, which includes restricted shares.
Nuvectis Pharma vice president receives new equity grant. Nuvectis Pharma, Inc. reported that its Vice President of Finance, Michael J. Carson, was awarded 61,200 shares of restricted common stock on January 6, 2026. The grant was priced at $0 per share, reflecting a stock award rather than an open-market purchase.
The 61,200 restricted shares will vest in equal annual installments over three years, beginning on the first anniversary of the grant date, and are conditioned on Mr. Carson’s continued service. After this grant, Mr. Carson beneficially owns a total of 200,118 shares of Nuvectis Pharma common stock, including restricted shares.
Nuvectis Pharma (NVCT) reported an insider purchase by Chairman & CEO Ron Bentsur. On 11/05/2025, he bought 5,000 shares of common stock at $5.72 per share (transaction code P). Following the trade, his directly held beneficial ownership totals 3,525,924 shares.
The total includes 676,759 shares of restricted stock, as noted in the footnote. Bentsur is listed as Director, Chairman & CEO, and a 10% Owner, with the reported holdings shown as Direct (D).
Nuvectis Pharma (NVCT) director reported an open-market purchase of 13,000 shares on November 5, 2025 at a weighted average price of $5.79. After the transaction, the director beneficially owned 78,150 shares directly and 415 shares indirectly as custodian for a son. The filing notes the purchase was executed through multiple same-day trades within a price range of $5.77 to $5.81, consolidated as a single line item.
Nuvectis Pharma (NVCT): Director Matthew Kaplan purchased 11,000 shares of common stock on 11/05/2025 in an open‑market transaction coded “P” at a weighted average price of $5.84. Following this trade, he beneficially owns 124,760 shares, held directly.
The filing notes the price was a weighted average across multiple same‑day trades within a $5.81–$5.88 range, and detailed breakdowns are available upon request.
Nuvectis Pharma, Inc. filed an 8‑K to furnish a press release providing a corporate update and financial results for the third quarter ended September 30, 2025. The press release is included as Exhibit 99.1 and, as stated, the information is being furnished and not deemed filed under the Exchange Act.
The company’s common stock trades on the Nasdaq Capital Market under the symbol NVCT. The filing also includes the iXBRL cover page as Exhibit 104.
Nuvectis Pharma (NVCT) reported Q3 2025 results showing higher operating spending as clinical programs progressed and licensing costs increased. Cash and cash equivalents were $35.4 million as of September 30, 2025, compared with $18.5 million at year-end 2024. The company posted a Q3 net loss of $7.5 million and a nine‑month net loss of $19.1 million. A warrant term extension recorded as an $2.4 million effect increased the total net loss attributable to common shareholders in Q3.
Operating drivers: R&D expense rose to $5.8 million in Q3 (from $2.8 million) mainly due to a $2.0 million license fee for NXP900 and higher clinical costs; G&A was $2.0 million (from $1.5 million). Year‑to‑date, R&D reached $13.1 million and G&A $6.9 million. To fund operations, Nuvectis raised capital via equity: in February 2025 it sold 3,105,000 shares at $5.00 for $14.0 million net, and in Q3 it sold 1,707,309 shares under its ATM for $13.5 million gross ($13.1 million net). Management believes current cash funds planned operations for at least 12 months.
Pipeline: NXP900 advanced into Phase 1b in August 2025; a DDI study classified it as a weak CYP3A inhibitor. The company issued a final update for NXP800 in July and will not pursue further development in ovarian cancer while assessing other indications.
Nuvectis Pharma (NVCT) reported a Form 4 for director Juan Sanchez showing the acquisition of 30,000 shares of restricted common stock on 09/22/2025 at a stated price of $0. The award vests in equal annual installments over three years beginning on the first anniversary of the grant date, contingent on his continued service on the Board.
After the reported transaction, Dr. Sanchez beneficially owned 65,150 shares directly and 415 shares indirectly as custodian for his son.
Nuvectis Pharma (NVCT) reported an initial Form 3 for a director with an event date of 09/22/2025. The filing lists beneficial ownership of 35,150 shares of common stock (direct), plus 295 shares (indirect) and 120 shares (indirect) held as custodian for a son. Table II shows no derivative securities. The form was signed by Juan Sanchez on 10/31/2025.